Skip to main content
. 2008 Dec 1;2008:305087. doi: 10.1155/2008/305087

Figure 1.

Figure 1

Effects of 10−8  M captopril (CPT, (a) and (b)), zofenoprilat (ZOF, (a) and (c)), lisinopril (LIS, (a) and (d)), enalaprilat (ENA, (a) and (e)) and bradykinin (BK, (a) and (f)) on endothelin-1 secretion (expressed as % of control) by vascular endothelial cells derived from umbilical cord vein after 8 hours of incubation both alone and in the presence of either Des-Arg9-[Leu8]-BK, that is, a bradykinin B1 receptor antagonist (B1ra, 10−6  M), or D-Arg-[Hyp3, Thi5,8, D-phe7]-BK, that is, a bradykinin B2 receptor antagonist (B2ra, 10−6  M), or the NO synthase competitive inhibitor Nω-nitro-L-arginine methyl ester (L-NA, 3 × 10−3  M). (A) P < .0008 or less versus CPT, ZOF, LIS, ENA, and BK; (B) P < .04 or less versus ZOF; (C) P < .0005 or less versus CPT+B1ra; (D) P < .0003 or less versus ZOF+B1ra, ZOF+B2ra, and ZOF+L-NA; (E) P < .002 versus ZOF+B1ra; (F) P < .0001 versus LIS+B1ra; (G) P < .0002 or less versus ENA+B1ra; (H) P < .0001 versus BK+B1ra.